Every manufacturer program for these drugs carries two prices, and they are aimed at two different people. One is a copay card that works only alongside commercial insurance that already covers the medicine. The other is a self-pay price anyone can use and nobody advertises as loudly. Confusing them is the commonest way a reader concludes the branded product costs $25, and the coverage machinery behind the first price is in the coverage article. Everything below was read from the programs’ own pages on September 14, 2026.
The card, and who actually qualifies
Novo Nordisk’s savings offer for Wegovy states that an eligible patient can “pay as little as $25” a month, “subject to a max savings of $100/month”.[1] Lilly’s savings card for Zepbound states that a patient whose commercial insurance covers the drug can “pay as little as $25 for a 1-month, 2-month, or 3-month prescription fill”.[3]
The conditions are where the money is. Lilly’s terms require that “you are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program”.[3] Novo’s page adds a detail worth knowing in the other direction: the Federal Employees Health Benefits Program, Affordable Care exchange plans and state employee plans are not federal or state healthcare programs for the purposes of that offer.[1]
So the card sorts by insurance rather than by need. A commercially insured patient whose plan already pays most of the cost pays $25. A patient with no coverage, or with Medicare, is sent to the other price entirely.
The self-pay price, and what it actually is
Novo’s pharmacy page lists $349 a month for Wegovy at 0.25, 0.5, 1, 1.7 and 2.4 mg, and $399 for the 7.2 mg high-dose pen. Patients new to the offer pay $199 for each of their first two months at 0.25 and 0.5 mg, an opening rate running through December 31, 2026.[2] The oral product is priced by dose instead, starting at $149 a month for 1.5 mg and reaching $299 for the 9 mg and 25 mg strengths.[2]
Lilly’s self-pay prices for the Zepbound KwikPen are dose-indexed throughout: $299 at 2.5 mg, $399 at 5 mg, and $449 from 7.5 mg to 15 mg.[3] A commercially insured patient whose plan does not cover Zepbound pays $499 a fill through the savings card, which is more than the self-pay price at every dose.
Both manufacturers therefore ship both pricing structures discussed in the price-variation article: one flat rate across a ladder, and one that climbs with the dose. The distinction is not a compounded-market quirk.
The Medicare exception that contradicts the rule
The blanket statement that federal beneficiaries are locked out of manufacturer help is no longer accurate for one program. Novo’s page states that eligible Medicare patients pay $50 a month for Wegovy through a Medicare GLP-1 Bridge program, for adults with Medicare prescribed Wegovy “for weight loss only”.[1]
That is a narrow, product-specific and revocable arrangement rather than a change in the rules, and it sits beside a copay card that still excludes the same population. It is also the single figure on this page most likely to be out of date first. The durable reading is the shape: who a program is for is a term, not a courtesy, and the term is published.
What a copay card costs everyone else
The federal exclusion is not an oversight. Coupons are banned in the federal programs, and economists have used that ban as a natural experiment. A study of drugs without generic substitutes estimated that introducing a coupon increased quantity sold by 23% to 25% in the commercial segment relative to Medicare Advantage, where coupons are prohibited. Modeling the resulting negotiations, it estimated that net-of-rebate prices are 8% higher because coupons are available.[4]
That is the trap under the trap. A card that moves one person’s bill to $25 is estimated to move the underlying price up for the plans, employers and premium-payers financing it. It is a transfer, not a discount, and the direction of the transfer is invisible at the pharmacy counter.
Expiry, caps, and the arithmetic of a 28-day month
Both cards carry an end date. Lilly’s states that the “card expires and savings end on 12/31/2026”, and Novo’s pricing is stated as subject to update after the same date.[1][3] Novo’s page also reserves the right to modify or cancel the program at any time.[2]
The caps bind before the dates do. Wegovy’s card saves at most $100 a month; Zepbound’s saves at most $1,300 in a calendar year.[1][3] And the unit is not a calendar month. Novo defines a month as one box of four pens; Lilly defines a one-month fill as 28 days and up to one KwikPen.[2][3] Four weeks is 28 days against a 30.44-day average month, so a year holds just over thirteen of those fills, and $349 thirteen times is $4,537 rather than the $4,188 that twelve implies. The general form of that calculation is in the annual-cost article, and it can be run on any quoted figure in the cost calculator.
Where this lands against the cash market
The self-pay programs are routinely described as having closed the gap with compounded telehealth. Against the prices recorded on this site they have closed it only at the top of the field. Of the 459 advertised compounded semaglutide injection prices here, 14 — 3% — are at or above Wegovy’s $349. Of the 415 compounded tirzepatide injection prices, 8 are at or above Zepbound’s $449.
So the manufacturer cash price now undercuts the dearest few percent of the cash market and remains roughly double its median. That is a real change from a list price in four figures, and it is not the same claim as parity. It also compares an FDA-approved product against preparations that are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before dispensing, which is the comparison the comparison article argues is not a like-for-like price at all. The ordered cash field is the price board.
The case where the card costs more than no card
Lilly’s program contains an instructive inversion. A patient with commercial insurance that does not cover Zepbound pays $499 a fill through the savings card.[3] The self-pay route, open to the same person, is $299 to $449 depending on dose.[3] The card branded as the discount is the more expensive of the two options at every strength.
That is not a hidden term; both figures sit on the same page. It survives because the two prices are presented as answers to different questions — one about insurance status, one about purchasing route — and a reader who answers the first question honestly never reaches the second. Novo’s pages carry the same shape in a milder form, since its self-pay pricing for the oral product climbs by dose while the pen price is held flat across five strengths.[2]
Whether the saving survives the course
An annual cap assumes an annual course. A 2026 national survey of 440 United States adults who had started and discontinued a GLP-1 found 54.6% stopped within six months and 79.7% within twelve, with cost the most frequently cited reason at 36.1% and lack of insurance coverage cited by 28.2%.[5] More than a third of that group, 35.4%, reported having used a copayment coupon.
Read together, those figures describe a population that takes the card, does not reach the cap, and stops for the price anyway. A savings program is a discount on a month, not a solution to a chronic-disease budget, and the evidence on what stopping does is the reason that distinction matters.
What will be wrong first
Every number above is dated to a single day, and this is the fastest moving page in this section. Self-pay prices have been revised more than once, the opening rates carry explicit end dates, the cards expire on December 31, 2026, and the Medicare arrangement is newer than any of it.
What does not move is the structure: a card conditioned on the insurance a reader already has, a self-pay price conditioned on nothing, a cap, an expiry, and a unit that is 28 days rather than a month. Checking those five things at the source takes a few minutes and settles more than any summary can, including this one. Whether whatever is paid can be paid pre-tax is a separate question, answered in the HSA and FSA article, and what the cash sellers publish is recorded in the seller write-ups.